PURPOSE: To assess locoregional outcomes of inflammatory breast cancer (IBC) patients who received standard fractionation radiation with daily skin bolus and taxanes as part of combined-modality therapy (CMT). METHODS AND MATERIALS: We retrospectively reviewed the charts of 107 patients diagnosed with IBC between January 1995 and March 2006 who presented to our department for adjuvant radiation therapy (RT). RESULTS: All patients received chemotherapy (95% anthracycline and 95% taxane), modified radical mastectomy, and RT to the chest wall and regional lymphatics using standard fractionation to 50 Gy and daily skin bolus. The RT to the chest wall was delivered via electrons (55%) or photons (45%) in daily fractions of 180 cGy (73%) or 200 cGy (27%). Scar boost was performed in 11%. A majority (84%) of patients completed the prescribed treatment. Median follow-up was 47 months (range, 10-134 months). Locoregional control (LRC) at 3 years and 5 years was 90% and 87%, respectively. Distant metastases-free survival (DMFS) at 3 years and 5 years was 61% and 47%, respectively. CONCLUSIONS: Excellent locoregional control was observed in this population of IBC patients who received standard fractionation radiation with daily skin bolus and taxanes as part of combined-modality therapy. Distant metastases-free survival remains a significant therapeutic challenge. Copyright 2010 Elsevier Inc. All rights reserved.
PURPOSE: To assess locoregional outcomes of inflammatory breast cancer (IBC) patients who received standard fractionation radiation with daily skin bolus and taxanes as part of combined-modality therapy (CMT). METHODS AND MATERIALS: We retrospectively reviewed the charts of 107 patients diagnosed with IBC between January 1995 and March 2006 who presented to our department for adjuvant radiation therapy (RT). RESULTS: All patients received chemotherapy (95% anthracycline and 95% taxane), modified radical mastectomy, and RT to the chest wall and regional lymphatics using standard fractionation to 50 Gy and daily skin bolus. The RT to the chest wall was delivered via electrons (55%) or photons (45%) in daily fractions of 180 cGy (73%) or 200 cGy (27%). Scar boost was performed in 11%. A majority (84%) of patients completed the prescribed treatment. Median follow-up was 47 months (range, 10-134 months). Locoregional control (LRC) at 3 years and 5 years was 90% and 87%, respectively. Distant metastases-free survival (DMFS) at 3 years and 5 years was 61% and 47%, respectively. CONCLUSIONS: Excellent locoregional control was observed in this population of IBCpatients who received standard fractionation radiation with daily skin bolus and taxanes as part of combined-modality therapy. Distant metastases-free survival remains a significant therapeutic challenge. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: Jing Li; Ana M Gonzalez-Angulo; Pamela K Allen; Tse K Yu; Wendy A Woodward; Naoto T Ueno; Anthony Lucci; Savitri Krishnamurthy; Yun Gong; Melissa L Bondy; Wei Yang; Jie S Willey; Massimo Cristofanilli; Vicente Valero; Thomas A Buchholz Journal: Oncologist Date: 2011-12-06
Authors: Hideko Yamauchi; Wendy A Woodward; Vicente Valero; Ricardo H Alvarez; Anthony Lucci; Thomas A Buchholz; Takayuki Iwamoto; Savitri Krishnamurthy; Wei Yang; James M Reuben; Gabriel N Hortobágyi; Naoto T Ueno Journal: Oncologist Date: 2012-05-14
Authors: Zsolt Horváth; László Torday; Erika Hitre; Erna Ganofszky; Eva Juhos; Ferenc Czeglédi; László Urbán; Csaba Polgár; István Láng; Sándor Eckhardt; Miklós Kásler Journal: Pathol Oncol Res Date: 2010-12-14 Impact factor: 3.201
Authors: Wendy A Woodward; Penny Fang; Lisa Arriaga; Hui Gao; Evan N Cohen; James M Reuben; Vicente Valero; Huong Le-Petross; Lavinia P Middleton; Gildy V Babiera; Eric A Strom; Welela Tereffe; Karen Hoffman; Benjamin D Smith; Thomas A Buchholz; George H Perkins Journal: Int J Radiat Oncol Biol Phys Date: 2017-05-03 Impact factor: 8.013
Authors: R de Haan; E van Werkhoven; M M van den Heuvel; H M U Peulen; G S Sonke; P Elkhuizen; M W M van den Brekel; M E T Tesselaar; C Vens; J H M Schellens; B van Triest; M Verheij Journal: BMC Cancer Date: 2019-09-10 Impact factor: 4.430